{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:18:45Z","timestamp":1792063125045,"version":"4.4.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.jaad.2011.06.001","type":"journal-article","created":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T02:21:51Z","timestamp":1316053311000},"page":"699-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":211,"title":["Melasma: A comprehensive update"],"prefix":"10.1016","volume":"65","author":[{"given":"Vaneeta M.","family":"Sheth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2011.06.001_bib1","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-2133.2008.08882.x","article-title":"Guidelines for topical photodynamic therapy: update","volume":"159","author":"Morton","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/jid.1962.136","article-title":"Melanogenesis in human skin following exposure to long-wave ultraviolet and visible light","volume":"39","author":"Pathak","year":"1962","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib3","unstructured":"Mahmoud BH, Hexsel CL, Owen MR, Liu Y, Kollias N, Lim HW, et\u00a0al. Impact of long wavelength UVA and visible light on melanocompetent skin. Presented in poster form at the 2008 American Society for Laser Medicine and Surgery Meeting, Kissimmee, FL, April 2-6, 2008."},{"key":"10.1016\/j.jaad.2011.06.001_bib4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1751-1097.2007.00286.x","article-title":"Effects of visible light on the skin","volume":"84","author":"Mahmoud","year":"2008","journal-title":"Photochem Photobiol"},{"key":"10.1016\/j.jaad.2011.06.001_bib5","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1468-3083.2007.02185.x","article-title":"Evaluation of the effectiveness of broad-spectrum sunscreen in the prevention of chloasma in pregnant women","volume":"21","author":"Lakhdar","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2011.06.001_bib6","first-page":"15","article-title":"Les signes dermatologiques physiologiques de la grossesse","volume":"126","author":"Khadir","year":"1999","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2011.06.001_bib7","first-page":"92","article-title":"The efficacy of a broad-spectrum sunscreen in the treatment of melasma","volume":"32","author":"V\u00e1zquez","year":"1983","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2011.06.001_bib8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jaad.2006.02.009","article-title":"The treatment of melasma: a review of clinical trials","volume":"55","author":"Gupta","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/1523-1747.ep12701679","article-title":"Mechanism of depigmentation by hydroquinone","volume":"62","author":"Jimbow","year":"1974","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1034\/j.1600-0749.2003.00029.x","article-title":"Chemical and instrumental approaches to treat hyperpigmentation","volume":"16","author":"Briganti","year":"2003","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jaad.2011.06.001_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF01867498","article-title":"Hydroquinone poisoning","volume":"183","author":"Oettel","year":"1956","journal-title":"Arch Exp Pathol Pharmacol"},{"key":"10.1016\/j.jaad.2011.06.001_bib12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archderm.1966.01600230093025","article-title":"Hydroquinone and psoralens in the therapy of hypermelanosis and vitiligo","volume":"93","author":"Fitzpatrick","year":"1966","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/jama.1965.03090220018004","article-title":"Topical use of hydroquinone for depigmentation","volume":"194","author":"Spencer","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2011.06.001_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1365-4362.2003.01621.x","article-title":"A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma","volume":"42","author":"Haddad","year":"2003","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib15","first-page":"67","article-title":"Efficacy and safety of a new triple-combination agent for the treatment of facial melasma","volume":"72","author":"Taylor","year":"2003","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2011.06.001_bib16","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1365-4632.2003.02017.x","article-title":"Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma","volume":"42","author":"Guevara","year":"2003","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546630050517333","article-title":"A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma","volume":"11","author":"Ennes","year":"2000","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2011.06.001_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-4362.1998.00499.x","article-title":"Topical hydroquinone in the treatment of some hyperpigmentary disorders","volume":"37","author":"Amer","year":"1998","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib19","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0190-9622(00)90257-3","article-title":"Exogenous ochronosis","volume":"42","author":"Kramer","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0190-9622(88)70126-7","article-title":"Exogenous ochronosis in the United States","volume":"18","author":"Lawrence","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-4632.2008.02719.x","article-title":"Complications of chronic use of skin lightening cosmetics","volume":"47","author":"Olumide","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib22","unstructured":"US Department of Health and Human Services, Food and Drug Administration. Skin bleaching drug products for over-the-counter human use; proposed rule. 71 Federal Register 51146-5115521 (2006) (codified at 21 CFR \u00a7310)."},{"key":"10.1016\/j.jaad.2011.06.001_bib23","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2007.02.020","article-title":"The safety of hydroquinone: a dermatologist\u2019s response to the 2006 Federal Register","volume":"57","author":"Levitt","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1473-2165.2005.40202.x","article-title":"Hydroquinone and its analogues in dermatology\u2014a potential health risk","volume":"4","author":"Westerhof","year":"2005","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1468-3083.2006.01670.x","article-title":"The safety of hydroquinone","volume":"20","author":"Nordlund","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2011.06.001_bib26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1529-8019.2007.00144.x","article-title":"Skin lightening preparations and the hydroquinone controversy","volume":"20","author":"Draelos","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2011.06.001_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0190-9622(00)90219-6","article-title":"The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies","volume":"42","author":"Fleischer","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1529-8019.2006.00085.x","article-title":"Retinoid therapy of pigmented disorders","volume":"19","author":"Ortonne","year":"2006","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2011.06.001_bib29","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1242\/jcs.107.4.1095","article-title":"Retinoic acid as modulator of UVB-induced melanocyte differentiation. Involvement of the melanogenic enzymes expression","volume":"107","author":"Romero","year":"1994","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jaad.2011.06.001_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2133.1993.tb03169.x","article-title":"Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial","volume":"129","author":"Griffiths","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.1994.01690060057005","article-title":"Topical retinoic acid (tretinoin) for melasma in black patients","volume":"130","author":"Kimbrough-Green","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib32","first-page":"868","article-title":"Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial","volume":"82","author":"Leenutaphong","year":"1999","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.jaad.2011.06.001_bib33","first-page":"45","article-title":"Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study","volume":"77","author":"Grimes","year":"2006","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2011.06.001_bib34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1346-8138.2002.tb00324.x","article-title":"Adapalene in the treatment of melasma: a preliminary report","volume":"29","author":"Dogra","year":"2002","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/archderm.1975.01630130042004","article-title":"A new formula for depigmenting human skin","volume":"111","author":"Kligman","year":"1975","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib36","first-page":"1","article-title":"Topical treatments for melasma and postinflammatory hyperpigmentation","volume":"11","author":"Lynde","year":"2006","journal-title":"Skin Therapy Lett"},{"issue":"4 pt 2","key":"10.1016\/j.jaad.2011.06.001_bib37","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0190-9622(86)70247-8","article-title":"Usefulness of retinoic acid in the treatment of melasma","volume":"15","author":"Pathak","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib38","first-page":"362","article-title":"A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation","volume":"74","author":"Grimes","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2011.06.001_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1473-2165.2007.00288.x","article-title":"A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma","volume":"6","author":"Cestari","year":"2007","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-4362.2001.01167-2.x","article-title":"Melasma treated with hydroquinone, tretinoin, and a fluorinated steroid","volume":"40","author":"Guevara","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib41","first-page":"153","article-title":"Cost-effectiveness of a fixed combination of hydroquinone\/tretinoin\/fluocinolone cream compared with hydroquinone alone in the treatment of melasma","volume":"6","author":"Cestari","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib42","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00018-005-5054-y","article-title":"Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future","volume":"62","author":"Kim","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jaad.2011.06.001_bib43","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0190-9622(87)70294-1","article-title":"Azelaic acid","volume":"17","author":"Nazzaro-Porro","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib44","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2165\/00003495-199141050-00007","article-title":"Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders","volume":"41","author":"Fitton","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2011.06.001_bib45","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0149-2918(98)80076-3","article-title":"Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients","volume":"20","author":"Lowe","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaad.2011.06.001_bib46","first-page":"58","article-title":"Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma","volume":"143","author":"Verallo-Rowell","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"10.1016\/j.jaad.2011.06.001_bib47","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1365-4362.1991.tb04362.x","article-title":"The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream","volume":"30","author":"Bali\u00f1a","year":"1991","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib48","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1524-4725.1996.tb00345.x","article-title":"The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions","volume":"22","author":"Garcia","year":"1996","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib49","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1524-4725.1999.08236.x","article-title":"Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid","volume":"25","author":"Lim","year":"1999","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib50","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-4632.2009.04336.x","article-title":"Effects of vitamin C vs. multivitamin on melanogenesis: comparative study in\u00a0vitro and in\u00a0vivo","volume":"49","author":"Choi","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib51","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-4632.2004.02134.x","article-title":"A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma","volume":"43","author":"Espinal-Perez","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib52","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.det.2007.04.012","article-title":"New and experimental treatments of chloasma and other hypermelanoses","volume":"25","author":"Picardo","year":"2007","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2011.06.001_bib53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.0906-6705.2005.00337.x","article-title":"DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in\u00a0vivo skin lightening potency","volume":"14","author":"Boissy","year":"2005","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib54","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-4362.2000.00943.x","article-title":"Topical liquiritin improves melasma","volume":"39","author":"Amer","year":"2000","journal-title":"Int J Dermatol"},{"issue":"5 suppl","key":"10.1016\/j.jaad.2011.06.001_bib55","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1016\/j.jaad.2005.12.039","article-title":"Treatment of melasma","volume":"54","author":"Rendon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/excr.1999.4692","article-title":"The protease-activated receptor 2 regulates pigmentation via keratinocyte-melanocyte interactions","volume":"254","author":"Seiberg","year":"2000","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jaad.2011.06.001_bib57","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1523-1747.2001.01291.x","article-title":"An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway","volume":"116","author":"Paine","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib58","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000063359","article-title":"Assessment of topical hypopigmenting agents on solar lentigines of Asian women","volume":"204","author":"Hermanns","year":"2002","journal-title":"Dermatology"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2011.06.001_bib59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1034\/j.1600-0625.12.s2.7.x","article-title":"The inhibitory effect of glycolic acid and lactic acid on melanin synthesis in melanoma cells","volume":"12","author":"Usuki","year":"2003","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib60","first-page":"28","article-title":"Chemical peeling\u2014evaluation of glycolic acid in varying concentrations and time intervals","volume":"67","author":"Gupta","year":"2001","journal-title":"Cosmetology"},{"key":"10.1016\/j.jaad.2011.06.001_bib61","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-4362.2001.01149.x","article-title":"Safety and efficacy of glycolic acid facial peel in Indian women with melasma","volume":"40","author":"Javaheri","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib62","first-page":"828","article-title":"The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study","volume":"28","author":"Sarkar","year":"2002","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1346-8138.2007.00211.x","article-title":"Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma","volume":"34","author":"Erbil","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib64","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1001\/archderm.138.12.1578","article-title":"Efficacy of glycolic acid peels in the treatment of melasma","volume":"138","author":"Hurley","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib65","first-page":"1032","article-title":"Comparative evaluation of beneficiary effects of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of melasma with glycolic acid peels","volume":"34","author":"Garg","year":"2008","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00042728-200502000-00005","article-title":"Lactic acid as a new therapeutic peeling agent in melasma","volume":"31","author":"Sharquie","year":"2005","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib67","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1524-4725.1999.08145.x","article-title":"The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups","volume":"25","author":"Grimes","year":"1999","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib68","first-page":"372","article-title":"Whitening effect of salicylic acid peels in Asian patients","volume":"32","author":"Hyo","year":"2006","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib69","first-page":"756","article-title":"Tretinoin peels versus glycolic acid peels in the treatment of melasma in dark-skinned patients","volume":"30","author":"Khunger","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib70","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0190-9622(97)70248-2","article-title":"Treatment of melasma with Jessner\u2019s solution versus glycolic acid: a comparison of clinical efficacy and evaluation of the predictive ability of Wood\u2019s light examination","volume":"36","author":"Lawrence","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib71","first-page":"1429","article-title":"Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner\u2019s solution chemical peels","volume":"32","author":"Sharquie","year":"2006","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib72","first-page":"512","article-title":"Focal trichloroacetic acid peel method for benign pigmented lesions in dark-skinned patients","volume":"30","author":"Chun","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib73","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1529-8019.2001.014001046.x","article-title":"Laser therapy for cutaneous hyperpigmentation and pigmented lesions","volume":"14","author":"Alster","year":"2001","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2011.06.001_bib74","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1524-4725.1994.tb00152.x","article-title":"Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser","volume":"20","author":"Taylor","year":"1994","journal-title":"J Dermatol Surg Oncol"},{"key":"10.1016\/j.jaad.2011.06.001_bib75","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1524-4725.1994.tb03707.x","article-title":"The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium: yttrium-aluminum-garnet laser. A comparative study","volume":"20","author":"Tse","year":"1994","journal-title":"J Dermatol Surg Oncol"},{"key":"10.1016\/j.jaad.2011.06.001_bib76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1524-4725.1999.08103.x","article-title":"Erbium:YAG laser resurfacing for refractory melasma","volume":"25","author":"Manaloto","year":"1999","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib77","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1524-4725.1999.08248.x","article-title":"Combination treatment of melasma with pulsed CO2 laser followed by Q-switched Alexandrite laser: a pilot study","volume":"25","author":"Nouri","year":"1999","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib78","first-page":"59","article-title":"Combined ultrapulse CO2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma: split-face design","volume":"29","author":"Angsuwarangsee","year":"2003","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib79","first-page":"7","article-title":"Fractional laser treatment for pigmentation and texture improvement","volume":"11","author":"Rahman","year":"2006","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.jaad.2011.06.001_bib80","first-page":"1645","article-title":"The treatment of melasma with fractional photothermolysis: a pilot study","volume":"31","author":"Rokhsar","year":"2005","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib81","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/lsm.20591","article-title":"Histologic and ultrastructural analysis of melasma after fractional resurfacing","volume":"40","author":"Goldberg","year":"2008","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.jaad.2011.06.001_bib82","first-page":"693","article-title":"Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients","volume":"34","author":"Li","year":"2008","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib83","first-page":"1196","article-title":"Intense pulsed light for the treatment of refractory melasma in Asian persons","volume":"30","author":"Wang","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib84","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1524-4725.2010.01564.x","article-title":"Clinicopathologic efficacy of copper bromide plus\/yellow laser (578 nm with 511 nm) for treatment of melasma in Asian patients","volume":"36","author":"Lee","year":"2010","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib85","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1365-2133.2007.07814.x","article-title":"Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial","volume":"156","author":"Khemis","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.06.001_bib86","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1011-1344(98)00212-7","article-title":"Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation induced pigmentation","volume":"47","author":"Maeda","year":"1998","journal-title":"J Photochem Photobiol"},{"key":"10.1016\/j.jaad.2011.06.001_bib87","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/00042728-200605000-00004","article-title":"Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial","volume":"32","author":"Lee","year":"2006","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2011.06.001_bib88","first-page":"320","article-title":"Efficacy of beta-carotene topical application in melasma: an open clinical trial","volume":"68","author":"Kar","year":"2002","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2011.06.001_bib89","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2133.2007.07934.x","article-title":"Mechanisms of\u00a0melanogenesis inhibition by 2,5-dimethyl-4-hydroxy-3(2H)-furanone","volume":"157","author":"Lee","year":"2007","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962211006281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962211006281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:20:13Z","timestamp":1759270813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962211006281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0190962211006281"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2011.06.001","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melasma: A comprehensive update","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2011.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}